

IN THE CLAIMS:

Please amend the claims as follows:

1-2. (Canceled)

3. (Currently Amended) A human monoclonal antibody or fragment thereof, wherein the antibody is denoted number 11, which is produced by hybridoma ATCC PTA-2308 or 72 (produced by hybridomas ATCC PTA 2308 and PTA 2309, respectively), or produced by a hybridoma denoted as F1 102 (ATCC PTA 3337), or F4 465 (ATCC PTA 3338), or denoted as F2 103 (ATCC PTA 3302 and PTA 3303, heavy and light chain, respectively), F5 77 (ATCC PTA 3304 and PTA 3305, heavy and light chain, respectively), or F5 157 (ATCC PTA 3306 and PTA 3307, heavy and light chain, respectively).

4-5. (Canceled)

6. (Currently Amended) The human monoclonal antibody fragment of any of claims 3 to 5, or 79 to 84, wherein the fragment comprises an scFv, Fab, Fab', or F(ab')₂ fragment.

7. (Canceled)

8. (Currently Amended) A detectably labeled human monoclonal antibody, wherein the antibody is produced by the hybridoma or is the antibody of any of claims 3 to 5 or 79 to 81.

9-22. (Canceled)

23. (Currently Amended) The A pharmaceutical formulation including the human monoclonal antibody of any of claims 3 to 5, or 79 to 84 further comprising a pharmaceutical formulation.

24. (Currently Amended) A host cell that expresses the antibody of any of claims 3 to 5 or 79 to 84.

25. (Currently Amended) A nucleic acid that encodes the antibody of any of claims 3 to 5 or 79 to 84.

26. (Previously presented) A host cell containing the nucleic acid of claim 25.

27-29. (Canceled)

30. (Withdrawn) A method for modulating a CD40 activity comprising contacting a cell that expresses CD40 with a modulating amount of the antibody of claim 1.

31. (Withdrawn) The method of claim 30, wherein the CD40 is human.
32. (Withdrawn) The method of claim 30, wherein the CD40 activity is increased.
33. (Withdrawn) The method of claim 32, wherein the increased CD40 activity comprises increased CD95, CD80 or CD86 expression.
34. (Withdrawn) The method of claim 32, wherein the increased CD40 activity comprises increased cell proliferation.
35. (Withdrawn) The method of claim 30, wherein the CD40 activity is decreased.
36. (Withdrawn) The method of claim 35, wherein the decreased CD40 activity comprises decreased CD95, CD80 or CD86 expression.
37. (Withdrawn) The method of claim 36, wherein the decreased CD40 activity comprises decreased cell proliferation.
38. (Withdrawn) The method of claim 37, wherein the decreased CD40 activity inhibits CD40L stimulated cell proliferation.
39. (Withdrawn) The method of claim 30, further comprising contacting the cell with a CD40 ligand.
40. (Withdrawn) The method of claim 30, wherein the antibody has the binding specificity of the antibody denoted as no. 11 or 72, or the antibody produced by the hybridoma denoted as F1-102, F5-152, F2-103, F5-77, F5-157 or F4-465.
41. (Withdrawn) The method of claim 30, wherein the antibody is denoted as no. 11 or 72, or the antibody produced by the hybridoma denoted as F1-102, F5-152, F2-103, F5-77, F5-157 or F4-465.
42. (Withdrawn) The method of claim 31, wherein the antibody has a CD40 modulating activity of the antibody denoted as no. 11 or 72, or the antibody produced by the hybridoma denoted as F1-102, F5-152, F2-103, F5-77, F5-157 or F4-465.
43. (Withdrawn) A method of increasing a CD40 activity in a subject comprising administering to the subject an amount of a human anti-CD40 antibody that increases a CD40 activity.
44. (Withdrawn) A method of decreasing a CD40 activity in a subject comprising administering to the subject an amount of a human anti-CD40 antibody that decreases a CD40 activity.

45. (Withdrawn) A method of ameliorating an immune disorder or inhibiting an undesirable immune response in a subject comprising administering to the subject an amount of a human anti-CD40 antibody that decreases a CD40 activity thereby ameliorating the immune disorder or inhibiting the undesirable immune response.
46. (Withdrawn) The method of claim 45, wherein the undesirable immune response comprises host rejection of a transplanted cell, tissue or organ.
47. (Withdrawn) The method of claim 45, wherein the undesirable immune response comprises inflammation.
48. (Withdrawn) The method of claim 45, wherein the immune disorder comprises autoimmunity.
49. (Withdrawn) The method of claim 45, wherein the immune disorder comprises a lymphoma, a leukemia or a myeloma.
50. (Withdrawn) A method of ameliorating an immune disorder in a subject comprising administering to the subject an amount of a human anti-CD40 antibody that increases a CD40 activity thereby ameliorating the immune disorder.
51. (Withdrawn) The method of claim 50, wherein the immune disorder comprises an immunodeficiency.
52. (Withdrawn) The method of claim 50, wherein the immune disorder comprises a cell proliferative disorder.
53. (Withdrawn) The method of claim 52, wherein the cell proliferative disorder comprises benign hyperplasia or a cancer.
54. (Withdrawn) A method of inducing or stimulating an immune response in a subject, comprising administering to the subject an amount of a human anti-CD40 antibody that increases a CD40 activity thereby inducing or stimulating an immune response.
55. (Withdrawn) The method of claim 54, wherein the immune response is stimulated against a cell proliferative disorder or an infection by a pathogen.
56. (Withdrawn) The method of claim 55, wherein the cell proliferative disorder comprises a tumor.
57. (Withdrawn) The method of claims 45, 50 or 54, wherein the method is performed prophylactically.

58. (Withdrawn) A method of detecting the presence of CD40 in a sample or a cell, comprising contacting a sample having or suspected of having CD40, or a cell expressing or suspected of expressing CD40, with the antibody of claim 1, and detecting the presence of CD40 in the sample or cell.
59. (Withdrawn) The method of claim 58, wherein the sample comprises a tissue, fluid or other specimen from a subject.
60. (Withdrawn) The method of claim 59, wherein the cell is in a subject.
61. (Withdrawn) A method of detecting the presence of a disorder associated with increased or decreased CD40 expression in a human, comprising contacting a sample having or suspected of having CD40 or a cell expressing or suspected of expressing CD40, wherein the sample or cell is from or present in the human, with the human anti-CD40 antibody of claim 1, and detecting the presence of increased or decreased CD40 expression in the sample or cell relative to a control thereby detecting the presence of a disorder associated with increased or decreased CD40 expression in the human.
- 62-64. (Canceled)
65. (Currently Amended) A human monoclonal antibody, wherein the antibody comprises heavy-chain variable sequence and light-chain variable sequence of the antibody selected from the antibodies denoted as number 11, which is produced by hybridoma ATCC PTA-2308 (produced by hybridomas ATCC PTA 2308 and PTA 2309, respectively), or selected from the antibodies produced by a hybridoma denoted as F1-102 (ATCC PTA-3337), or and F4-465 (ATCC PTA-3338).
66. (Previously presented) A human monoclonal antibody, wherein the antibody comprises heavy-chain variable sequence and light-chain variable sequence encoded by the pair of sequences set forth as SEQ ID NO:10 and SEQ ID NO:11; SEQ ID NO:12 and SEQ ID NO:13; or SEQ ID NO:14 and SEQ ID NO:15.
67. (Currently Amended) A human monoclonal antibody, wherein the antibody comprises a heavy-chain variable sequence and a light-chain variable sequence encoded by heavy and light chain sequences selected from F2-103-[[H]] heavy chain (ATCC PTA-3302) and F2-103-[[L]] light chain (ATCC PTA-3303); F5-77-[[H]] heavy chain (ATCC PTA-

3304) and F5-77-[[L]] light chain (ATCC PTA-3305); and F5-157-[[H]] heavy chain (ATCC PTA-3306) and F5-157-[[L]] light chain (ATCC PTA-3307).

68. (Previously presented) A hybridoma denoted as ATCC PTA-2308.
69. (Previously presented) A hybridoma denoted as ATCC PTA-2309.
70. (Previously presented) A hybridoma denoted as ATCC PTA-3337.
71. (Previously presented) A hybridoma denoted as ATCC PTA-3338.
72. (Previously presented) A hybridoma denoted as ATCC PTA-2308.
73. (Previously presented) A cell line denoted as ATCC PTA-3302.
74. (Previously presented) A cell line denoted as ATCC PTA-3303.
75. (Previously presented) A cell line denoted as ATCC PTA-3304.
76. (Previously presented) A cell line denoted as ATCC PTA-3305.
77. (Previously presented) A cell line denoted as ATCC PTA-3306.
78. (Previously presented) A cell line denoted as ATCC PTA-3307.

Please add the following new claims:

79. (New) A human monoclonal antibody or fragment thereof, wherein the antibody is denoted number 72, which is produced by hybridoma ATCC PTA-2309.
80. (New) A human monoclonal antibody or fragment thereof, wherein the antibody is produced by a hybridoma denoted as F1-102 (ATCC PTA-3337).
81. (New) A human monoclonal antibody or fragment thereof, wherein the antibody is produced by a hybridoma denoted as F4-465 (ATCC PTA-3338).
82. (New) A human monoclonal antibody or fragment thereof, wherein the antibody is denoted as F2-103, in which heavy chain of the antibody is produced by ATCC PTA-3302, and in which light chain of the antibody is produced by ATCC PTA-3303.
83. (New) A human monoclonal antibody or fragment thereof, wherein the antibody is denoted as F5-77, in which heavy chain of the antibody is produced by ATCC PTA-3304, and in which light chain of the antibody is produced by ATCC PTA-3305.
84. (New) A human monoclonal antibody or fragment thereof, wherein the antibody is denoted as F5-157, in which heavy chain of the antibody is produced by ATCC PTA-3306, and , in which light chain of the antibody is produced by PTA-3307.

85. (New) The human monoclonal antibody or fragment thereof of any of claims 82 to 84, wherein the antibody or fragment thereof is detectably labeled.
86. (New) A human monoclonal antibody, wherein the antibody comprises heavy-chain variable sequence and light-chain variable sequence of the antibody denoted as number 72, which is produced by hybridoma PTA-2309.
87. (New) A human monoclonal antibody, wherein the antibody comprises heavy-chain variable sequence and light-chain variable sequence of the antibody produced by a hybridoma denoted as F1-102 (ATCC PTA-3337).
88. (New) A human monoclonal antibody, wherein the antibody comprises heavy-chain variable sequence and light-chain variable sequence of the antibody produced by a hybridoma denoted as F4-465 (ATCC PTA-3338).